JPM vs NAKA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NAKA exhibits critical financial distress, anchored by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. The company has suffered a catastrophic price collapse, falling from a 52-week high of $34.77 to $0.24, reflecting a loss of nearly 99% of its value. Operational efficiency is non-existent with an operating margin of -514.88% and a Quick Ratio of 0.10, signaling a severe liquidity crisis. Despite a 'strong_buy' analyst consensus, the data reveals a company with shrinking revenues (-26.3%) and negative returns on equity.
Compare Another Pair
Related Comparisons
JPM vs NAKA: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nakamoto Inc. (NAKA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.